| Pre (t0) | Post (t1) |
---|---|---|
COGBAT norm percentile (≥ 50 = healthy) | ||
 Planning ability (median; IQR) | 30 (11.25 to 42.50) | 65 (35 to 80) |
 Figural memory (median; IQR) | 22.5 (0 to 50) | 45 (16.25 to 75) |
Patient characteristics and biomarkers | ||
 Age (years; median) | 73 | – |
 Sex (female) | 19/40 (47.5%) | – |
 MWT-B intelligence quotient (IQ) | 110.83 ± 16.3 | – |
 STS-score (%) | 5.16 (5.24) | – |
 Psychopharmacological medication (n) | 6 (15%) | – |
 Ejection fraction (%) | 35 ± 15 | 35 ± 16 |
 6 min walk distance test (m) | 366 ± 7 | 415 ± 115 |
 NT-ProBNP (ng/L) (median) | 3880 | 3627 |
 hsTnT (pg/mL) | 36 ± 33 | 46 ± 80 |
Pathogenesis and comorbidity | ||
 ICMP (%) | 21/40 (52.5%) | – |
 DCMP (%) | 19/40 (47.5%) | – |
 Implantable cardioverter defibrillator (%) | 15/40 (37.5%) | – |
 Prior cardiothoracic surgery (%) | 9/40 (22.5%) | – |
 Atrial fibrillation (%) | 20/40 (50%) | – |
 Prior stroke (%) | 4/40 (10%) | – |
 Increased retention values (> 1.3 mg/dL) (%) | 11/40 (27.5%) | – |
 Severe sleep apnea syndrome (%) | 4/40 (10%) | – |
 Diabetes mellitus (%) | 6/40 (15%) | – |
 Pulmonary disease | 8/40 (20%) | – |
 Cancer (%) | 1/40 (2.5%) | – |
Functional Mitral valve regurgitation (FMR) | ||
 FMR ≤ I° | 0 | 14/40 (35%) |
 FMR ≤ II° | 0 | 23/40 (57.5%) |
 FMR > II°–< III° | 4/40 (10%) | 3/40 (7.5%) |
 FMR III° | 11/40 (27.5%) | 0 |
 FMR IV° | 23/40 (57.5%) | 0 |
NYHA functional classification | ||
 NYHA I | 0 | 1/40 (2.5%) |
 NYHA II | 3/40 (7.5%) | 24/40 (60%) |
 NYHA III | 32/40 (80%) | 15/40 (37.5%) |
 NYHA IV | 5/40 (12.5%) | 0 |